Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca's area volume

Molecular Psychiatry

Volumn 21, Issue 8, 2016, Pages 1090-1098

  Fillman, S G ^a,b,c   Weickert, T W ^a,b,c   Lenroot, R K ^a,b,c   Catts, S V ^b,d,e   Bruggemann, J M ^b,c   Catts, V S ^a,b,c   Weickert, C S ^a,b,c  

^a Schizophrenia Research Institute   (Australia)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA;

ADULT; ARTICLE; BRAIN SIZE; BROCA AREA; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HUMAN; INFLAMMATION; INTELLIGENCE QUOTIENT; LANGUAGE; MALE; MEMORY; NEUROBIOLOGY; PARS OPERCULARIS; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; VERBAL MEMORY; WERNICKE AREA; BLOOD; BRAIN; BRAIN DISEASE; BRAIN MAPPING; IMAGE PROCESSING; INTELLIGENCE TEST; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS; VERBAL BEHAVIOR;

ADULT; BRAIN; BRAIN DISEASES; BRAIN MAPPING; BROCA AREA; CYTOKINES; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INTELLIGENCE TESTS; LANGUAGE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; VERBAL BEHAVIOR;

EID: 84937597775     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2015.90     Document Type: Article

References (71)

1. Tsuang MT, Lyons MJ, Faraone SV. Heterogeneity of schizophrenia. Conceptual models and analytic strategies. Br J Psychiatry 1990; 156: 17-26.
2. Müller N, Schwarz MJ. Immune system and schizophrenia. Curr Immunol Rev 2010; 6: 213-220.
3. Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010; 167: 261-280.
4. Nawa H, Takei N. Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines. Neurosci Res 2006; 56: 2-13.
5. Fillman SG, Cloonan N, Catts VS, Miller LC, Wong J, McCrossin T, et al. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry 2013; 18: 206-214.
6. Arolt V, Ambrée O. The question of pro-inflammatory immune activity in schizophrenia and the potential importance of anti-inflammatory drugs. Mod Trends Pharmacopsychiatri 2013; 28: 100-116.
7. Katila H, Appelberg B, Hurme M, Rimsn R. Plasma levels of interleukin-1β and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Neuroscience 1994; 12: 29-34.
8. Cazzullo CL, Sacchetti E, Galluzzo A, Panariello A, Colombo F, Zagliani A, et al. Cytokine profiles in drug-naive schizophrenic patients. Schizophr Res 2001; 47: 293-298.
9. Erbaǧci AB, Herken H, Köylüoglu O, Yilmaz N, Tarakçioglu M. Serum IL-1beta, sIL-2 R, IL-6, IL-8 and TNF-Alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediators Inflamm 2001; 10: 109-115.
10. Frommberger UH, Bauer J, Haselbauer P, Fräulin A, Riemann D, Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 1997; 247: 228-233.
11. Ganguli R, Yang Z, Shurin G, Chengappa KN, Brar JS, Gubbi AV, et al. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res 1994; 51: 1-10.
12. Kim YK, Kim L, Lee MS. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res 2000; 44: 165-175.
13. Kunz M, Ceres?r KM, Goi PD, Fries GR, Teixeira AL, Fernandes BS, et al. Serum levels of IL-6, IL-10 and TNF-a in patients with bipolar disorder and schizophrenia: differences in pro- And anti-inflammatory balance. Rev Bras Psiquiatr 2011; 33: 268-274.
14. Naudin J, Mège JL, Azorin JM, Dassa D. Elevated circulating levels of IL-6 in schizophrenia. Schizophr Res 1996; 20: 269-273.
15. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008; 63: 801-808.
16. Sirota P, Schild K, Elizur A, Djaldetti M, Fishman P. Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 75-83.
17. Zhang XY, Zhou DF, Zhang PY, Wu GY, Cao LY, Shen YC. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr Res 2002; 57: 247-258.
18. Toledo JB, Da X, Bhatt P, Wolk DA, Arnold SE, Shaw LM, et al. Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNI. PLoS One 2013; 8: e55531.
19. Balldin VH, Hall JR, Barber RC, Hynan L, Diaz-Arrastia R, O'Bryant SE. The relation between inflammation and neuropsychological test performance. Int J Alzheimer's Dis 2012; 2012: 703871.
20. Tobinick EL, Gross H. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurol 2008; 8: 27.
21. Alptekin K, Akvardar Y, Akdede BBK, Dumlu K, Isik D, Pirinçci F, et al. Is quality of life associated with cognitive impairment in schizophrenia?. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 239-244.
22. Fett A-KJ, Viechtbauer W, Dominguez M-d-G, Penn DL, van Os J, Krabbendam L. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-Analysis. Neurosci Biobehav Rev 2011; 35: 573-588.
23. Mattson DT, Berk M, Lucas MD. A neuropsychological study of prefrontal lobe function in the positive and negative subtypes of schizophrenia. J Genet Psychol 1997; 158: 487-494.
24. Weickert TW, Goldberg TE, Gold JM, Bigelow LB, Egan MF, Weinberger DR. Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Arch Gen Psychiatry 2000; 57: 907-913.
25. Amunts K, Weiss PH, Mohlberg H, Pieperhoff P, Eickhoff S, Gurd JM, et al. Analysis of neural mechanisms underlying verbal fluency in cytoarchitectonically defined stereotaxic space-The roles of Brodmann areas 44 and 45. NeuroImage 2004; 22: 42-56.
26. Blank SC, Scott SK, Murphy K, Warburton E, Wise RJS. Speech production: Wernicke, Broca and beyond. Brain 2002; 125: 1829-1838.
27. Poldrack RA, Wagner AD, Prull MW, Desmond JE, Glover GH, Gabrieli JD. Functional specialization for semantic and phonological processing in the left inferior prefrontal cortex. NeuroImage 1999; 10: 15-35.
28. Douaud G, Smith S, Jenkinson M, Behrens T, Johansen-Berg H, Vickers J, et al. Anatomically related grey and white matter abnormalities in adolescent-onset schizophrenia. Brain 2007; 130: 2375-2386.
29. Wisco JJ, Kuperberg G, Manoach D, Quinn BT, Busa E, Fischl B, et al. Abnormal cortical folding patterns within Broca's area in schizophrenia: evidence from structural MRI. Schizophr Research 2007; 94: 317-327.
30. Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA. Brain volume in first-episode schizophrenia: systematic review and meta-Analysis of magnetic resonance imaging studies. Br J Psychiatry 2006; 188: 510-518.
31. Powchik P, Davidson M, Haroutunian V, Gabriel SM, Purohit DP, Perl DP, et al. Postmortem studies in schizophrenia. Schizophr Bull 1998; 24: 325-341.
32. Catts VS, Wong J, Fillman SG, Fung SJ, Weickert CS. Increased expression of astrocyte markers in schizophrenia: association with neuroinflammation. Aust N Z J Psychaitry 2014; 48: 722-734.
33. Antonova E, Kumari V, Morris R, Halari R, Anilkumar A, Mehrotra R, et al. The relationship of structural alterations to cognitive deficits in schizophrenia: a voxel-based morphometry study. Biol Psychiatry 2005; 58: 457-467.
34. Cocchi L, Walterfang M, Testa R, Wood SJ, Seal ML, Suckling J, et al. Grey and white matter abnormalities are associated with impaired spatial working memory ability in first-episode schizophrenia. Schizophr Res 2009; 115: 163-172.
35. Ehrlich S, Brauns S, Yendiki A, Ho B-C, Calhoun V, Schulz SC, et al. Associations of cortical thickness and cognition in patients with schizophrenia and healthy controls. Schizophr Bull 2012; 38: 1050-1062.
36. Herold CJ, Lässer MM, Schmid LA, Seidl U. Hippocampal volume reduction and autobiographical memory deficits in chronic schizophrenia. Psychiatry Res 2012; 211: 189-194.
37. Wojtalik JA, Eack SM, Keshavan MS. Structural neurobiological correlates of Mayer-Salovery-Caruso Emotional Intelligence Test performance in early course schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013; 40: 207-212.
38. Yamada M, Hirao K, Namiki C, Hanakawa T, Fukuyama H, Hayashi T, et al. Social cognition and frontal lobe pathology in schizophrenia: a voxel-based morphometric study. NeuroImage 2007; 35: 292-298.
39. Palladino I, Salani F, Ciaramella A, Rubino IA, Caltagirone C, Fagioli S, et al. Elevated levels of circulating IL-18BP and perturbed regulation of IL-18 in schizophrenia. J Neuroinflamm 2012; 9: 206.
40. First MB, Williams JB, Spitzer RL, Gibbon M. Structured clinical interview for DSM-IV-TR axis I disorders, Patient Edition, 1st revision. Biometrics Research Department, New York State Psychiatric Insitutute: New York, NY, USA, 2007.
41. Bollini P, Pampallona S, Nieddu S, Bianco M, Tibaldi G, Munizza C. Indicators of conformance with guidelines of schizophrenia treatment in mental health services. Psychiatr Serv 2008; 59: 782-791.
42. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003; 64: 663-667.
43. Benton AL, Hamsher K. Multilingual Aphasia Examination, 2nd edn, AJA Associates: Iowa City, IA, USA, 1976.
44. Wechsler D. Wechsler Memory Scale, 3rd edn, The Psychological Corporation: San Antonio, TX, USA, 1997.
45. Wechsler D. Weschsler Adult Intelligence Scale-III. The Psychological Corporation: San Antonio, TX, USA, 1997.
46. Wechsler D. Wechsler Test of Adult Reading (WTAR). The Psychological Corporation: San Antonio, TX, USA, 2001.
47. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276.
48. FreeSurfer v5.1.0, Athinoula A. Martinos Center for Biomedical Imaging. Massachusetts, USA, 2005.
49. Grubbs FE. Procedures for detecting outlying observations in samples. Technometrics 1969; 11: 1-21.
50. Fillman SG, Sinclair D, Fung SJ, Webster MJ, Weickert CS. Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder. Transl Psychiatry 2014; 4: e365.
51. Bacher J, Wenzig K, Vogler M. SPSS twostep cluster: a first evaluation. Lehrstuhl fur Soziologie - Arbeits- und Diskussionspapiere 2004; 3-21.
52. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Ann Statistics 1995; 57, pp 289-300.
53. Basu A, Krady JK, Levison SW. Interleukin-1: a master regulator of neuroinflammation. J Neurosci Res 2004; 78: 151-156.
54. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-Analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011; 70: 663-671.
55. Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun 2006; 20: 532-545.
56. Cannon TD, Chung Y, He G, Sun DQ, Jacobson A, van Erp TGM, et al. Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk. Biol Psychiatry 2015; 77: 147-157.
57. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998; 83: 847-850.
58. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allerg Clin Immunol 2005; 115: 911-919.
59. Ransohoff RM, Brown MA. Innate immunity in the central nervous system. J Clin Invest 2012; 122: 1164-1171.
60. Roubenoff R, Harris TB, Abad LW, Wilson PW, Dallal GE, Dinarello CA. Monocyte cytokine production in an elderly population: effect of age and inflammation. J Gerontol A Biol Sci Med Sci 1998; 53: M20-M26.
61. Hwang Y, Kim J, Shin J-Y, Kim J-I, Seo J-S, Webster MJ, et al. Gene expression profiling by mRNA sequencing reveals increased expression of immune/inflammation-related genes in the hippocampus of individuals with schizophrenia. Transl Psychiatry 2013; 3: e321.
62. Banks WA, Lynch JL, Price TO. Cytokines and the blood-brain barrier. Seigel A, Zalcman SS (eds). Neuroimmunological Basis of Behavior. Springer: NY, 2009; 3-17.
63. Kanno K, Hirata Y, Imai T, Marumo F. Induction of nitric oxide synthase gene by interleukin in vascular smooth muscle cells. Hypertension 1993; 22: 34-39.
64. Lucas S-M, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. Br J Pharmacol 2006; 147: S232-S240.
65. Schwarcz R, Bruno JP, Muchowski PJ, Wu H-Q. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 2012; 13: 465-477.
66. Catts VS, Shannon Weickert C. Gene expression analysis implicates a death receptor pathway in schizophrenia pathology. PLoS One 2012; 7: e35511.
67. Fung SJ, Joshi D, Fillman SG, Weickert CS. High white matter neuron density with elevated cortical cytokine expression in schizophrenia. Biol Psychiatry 2014; 75: E5-E7.
68. Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010; 71: 138-149.
69. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995; 45: 51-55.
70. Laan W, Grobbee DE, Selten J-P, Heijnen CJ, Kahn RS, Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010; 71: 520-527.
71. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010; 363: 301-304.